Literature DB >> 33498521

Therapeutic Implications of TGFβ in Cancer Treatment: A Systematic Review.

Verónica Gómez-Gil1.   

Abstract

Transforming growth factor β (TGFβ) is a pleiotropic cytokine that participates in a wide range of biological functions. The alterations in the expression levels of this factor, or the deregulation of its signaling cascade, can lead to different pathologies, including cancer. A great variety of therapeutic strategies targeting TGFβ, or the members included in its signaling pathway, are currently being researched in cancer treatment. However, the dual role of TGFβ, as a tumor suppressor or a tumor-promoter, together with its crosstalk with other signaling pathways, has hampered the development of safe and effective treatments aimed at halting the cancer progression. This systematic literature review aims to provide insight into the different approaches available to regulate TGFβ and/or the molecules involved in its synthesis, activation, or signaling, as a cancer treatment. The therapeutic strategies most commonly investigated include antisense oligonucleotides, which prevent TGFβ synthesis, to molecules that block the interaction between TGFβ and its signaling receptors, together with inhibitors of the TGFβ signaling cascade-effectors. The effectiveness and possible complications of the different potential therapies available are also discussed.

Entities:  

Keywords:  SMAD; TGFβ; antisense oligonucleotides; cancer; drug target; epithelial to mesenchymal transition; metastasis; miRNA; siRNA; small molecule inhibitor

Year:  2021        PMID: 33498521      PMCID: PMC7864190          DOI: 10.3390/cancers13030379

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  151 in total

Review 1.  Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition.

Authors:  Carl-Henrik Heldin; Maréne Landström; Aristidis Moustakas
Journal:  Curr Opin Cell Biol       Date:  2009-02-23       Impact factor: 8.382

2.  Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK.

Authors:  Li Shang; Shu-Shan Jia; Hai-Ming Jiang; Hua Wang; Wen-Hua Xu; Chang-Jun Lv
Journal:  Tumour Biol       Date:  2015-01-29

3.  miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9.

Authors:  Zhihong Li; Bai Li; Liang Niu; Liang Ge
Journal:  Oncol Rep       Date:  2016-11-25       Impact factor: 3.906

4.  Regulation of Oral Squamous Cell Carcinoma Proliferation Through Crosstalk Between SMAD7 and CYLD.

Authors:  Wei-Li Ge; Jun-Feng Xu; Jun Hu
Journal:  Cell Physiol Biochem       Date:  2016-03-17

5.  MicroRNA-155 deletion promotes tumorigenesis in the azoxymethane-dextran sulfate sodium model of colon cancer.

Authors:  Kandy T Velázquez; Reilly T Enos; Jamie L McClellan; Taryn L Cranford; Ioulia Chatzistamou; Udai P Singh; Mitzi Nagarkatti; Prakash S Nagarkatti; Daping Fan; E Angela Murphy
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

Review 6.  TGF-β: duality of function between tumor prevention and carcinogenesis.

Authors:  Daniel R Principe; Jennifer A Doll; Jessica Bauer; Barbara Jung; Hidayatullah G Munshi; Laurent Bartholin; Boris Pasche; Chung Lee; Paul J Grippo
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

7.  Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer.

Authors:  Zahra Daman; Homa Faghihi; Hamed Montazeri
Journal:  Drug Dev Ind Pharm       Date:  2018-05-02       Impact factor: 3.225

8.  Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma.

Authors:  Jie-Jen Lee; Tao-Yeuan Wang; Chien-Liang Liu; Ming-Nan Chien; Ming-Jen Chen; Yi-Chiung Hsu; Ching-Hsiang Leung; Shih-Ping Cheng
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

9.  Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer.

Authors:  Ahmad Aljada; Ayman M Saleh; Moath Alkathiri; Heba Bani Shamsa; Ahmad Al-Bawab; Amre Nasr
Journal:  Breast Cancer (Auckl)       Date:  2015-04-09

10.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

View more
  2 in total

1.  Hypoxia Selectively Increases a SMAD3 Signaling Axis to Promote Cancer Cell Invasion.

Authors:  Karine Brochu-Gaudreau; Martine Charbonneau; Kelly Harper; Claire M Dubois
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

Review 2.  Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases.

Authors:  Ning Shi; Zhihong Wang; Hecheng Zhu; Weidong Liu; Ming Zhao; Xingjun Jiang; Jin Zhao; Caiping Ren; Yan Zhang; Longlong Luo
Journal:  Immunol Res       Date:  2022-02-11       Impact factor: 4.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.